Bausch+Lomb Travoflo: Interruption

July 06, 2013Filed under Print and Health, Beauty, Pharmaceutical
views
0
comments

Globally, Glaucoma is the second leading cause of blindness after cataract. In India, approximately 11 million people have lost their vision due to this incurable disease. Compliance is a major concern in treating Glaucoma as nearly 50% of patients admit non-continuous use of medications by 6 months after start of therapy. Multiple dosing limits patient’s adherence to the treatment and thereby, worsens the condition. Patients feel that the treatment of Glaucoma is inconvenient and interferes with their day-to-day life. Bausch+Lomb’s Travoflo is a convenient once-daily-dosing therapy for Glaucoma, which is aimed at improving patient compliance by reducing the number of interruptions and improving the overall outcome.

Advertising Agency:POINTBLANK Advertising, Mumbai, India
Director:Bindu Menon
Creative Head:Sujeesh Sukumaran 

Art Director:Pankaj Bhatia, Krishna Kumkar

Copywriter:Smruthy Nair, Guruguhan Iyer

Account Manager:Ruchelle Dias
Account Executive:Shreyas Pinglekar

Prev
press ‹ on your keyboard
press › on your keyboard
Next
Ads by the same Agency
:|